We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Group K Diagnostics Demonstrates KromaHealth Kit that Enables Lab-Quality Results at Point-of-Care

By LabMedica International staff writers
Posted on 29 Sep 2021

Group K Diagnostics (GKD; Philadelphia, PA, USA) demonstrated its KromaHealth Kit that enables point-of-care testing and fast results across a suite of various diagnostics at AACC 2021. More...

Every year, the global laboratory medicine community comes together at AACC to collaborate and create system-wide changes that improve patient outcomes and enhance the quality of life for all. The exhibition provides a platform to connect with the industry leaders making ground-breaking advancements in laboratory medicine, including clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, and lab management.

At this year’s AACC, GKD demonstrated its KromaHealth Kit which consists of a single-platform, versatile, point-of-care device, known as KromaHealth, paired with a mobile application used to read the test results, known as KromaViewer. Depending on the test, a user needs to simply place a few drops of blood, serum or urine on the device's testing sites to induce a color change that is translated into a clear diagnosis through an image processing algorithm. The process is simple and can be done in the physician's office with results provided before the patient leaves the physician’s office. The device is for investigational use only and its performance characteristics have not been established

GKD is currently developing the GKD Analytics Manager which is a dashboard for health system operators and researchers to monitor testing operations and collect anonymized results to analyze population health, disease management and compliance. GKD is also developing the MyGKD app which gives patients the ability view and track test results over time on their mobile phones. With this convenient access to their diagnostics, patients can own their results and be engaged in the effectiveness of their care.

Related Links:
Group K Diagnostics


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Immunofluorescence Analyzer
IFA System
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Molecular Diagnostics

view channel
Image: The mRNA Gene Biomarker Test uses standard blood samples to generate a probability score distinguishing schizophrenia from bipolar I disorder (photo courtesy of Laguna Diagnostics)

Blood Test Receives FDA Breakthrough Status to Differentiate Schizophrenia and Bipolar Disorder

Differentiating schizophrenia from bipolar I disorder in symptomatic patients is challenging because early presentations often overlap. Current diagnostic pathways rely heavily on subjective assessments... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.